Chunming Tang

Chunming Tang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in ACS Nano
Verified
Journal Article
Open access
GKGuang Kong
Guang Kong
JLJie Liu
Jie Liu
JWJuan Wang
Juan Wang
XYXiaohu Yu
Xiaohu Yu
CLCong Li
Cong Li
JFJin Fan
Jin Fan
Engineered extracellular vesicles play an increasingly important role in the treatment of spinal cord injury. In order to prepare more effective engineered extracellular vesicles, we biologically modified M2 microglia. Angiopep-2 (Ang2) is an oligopeptide that can target the blood-brain barrier. Through single-cell sequencing and immunofluorescence experiments, we confirmed that the expression of LRP-1, the targeted receptor of Ang2, was elevated after spinal cord injury. Subsequently, we integrated the Ang2 peptide segment into M2 microglia to obtain Ang2-EVs, which could successfully target the site of spinal cord injury. However, in order to improve the function of Ang2-EVs, we pretreated M2 microglia with melatonin, which has anti-inflammatory effects, to obtain M-Ang2-EVs. The results of single-nucleus sequencing of the mouse spinal cord verified that neurons and OPCs gradually transformed into subtypes related to nerve repair functions after treatment with M-Ang2-EVs. This is consistent with the sequencing and enrichment analysis of miRNAs contained in M-Ang2-EVs. We further verified through experiments that M-Ang2-EVs can promote microglia/macrophages to phagocytose sphingomyelin, promote axon remyelination and axon elongation, and maintain the integrity of the blood-spinal barrier. Since Ang2 can also target the blood-brain barrier, we found that M-Ang2-EVs can also reduce brain inflammation that results from spinal cord injury. Our study applied the Angiopep-2 peptide to spinal cord injury to enhance the targeting of injured cells, and successfully construct engineered extracellular vesicles that can target the spinal cord injury site and the brain.

21 August 2022 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YJYou Ji
You Ji
ZZZiting Zhang
Ziting Zhang
WHWenjun Hou
Wenjun Hou
MWMin Wu
Min Wu
HWHaisi Wu
Haisi Wu
HXHuae Xu
Huae Xu

1 January 2021 in Journal of Biomedical Research
Verified
Journal Article
Open access
PDF file
SWSiwan Wang
Siwan Wang
HJHui Jiang
Hui Jiang
JWJia Wang
Jia Wang
HWHaisi Wu
Haisi Wu
TWTing Wu
Ting Wu
HXHuae Xu
Huae Xu
As a well-known anticancer drug, paclitaxel (PTX), a first-line chemotherapeutic agent, remains unsatisfactory for gastric cancer therapy. It is reported that triptolide (TPL) could enhance the anti-gastric cancer effect of PTX. Considering the poor solubility of both drugs, we developed a red blood cell membrane-biomimetic nanosystem, an emerging tool in drug delivery, to co-load paclitaxel and triptolide (red blood cell membrane coated PTX and TPL co-loaded poly(lactic-co-glycolic acid) [PLGA] nanoparticles, RP(P/T)). The successful preparation was confirmed in terms of particle size, morphology, and surface markers assays. This biomimetic system could prolong circulation and escape immune surveillance. And these properties were verified by stability, in vitro drug release, and cellular uptake assays. Moreover, the MTT and colony formation assays demonstrated the superior anti-proliferation effect of the RP(P/T) to free drugs. The enhanced antitumor effects of RP(P/T) on migration and invasion were also evaluated by wound-healing and transwell assays. Overall, the bionic co-delivery nanoplatform with improved efficacy in vitro is a promising therapy for gastric cancer.

18 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TWTing Wu
Ting Wu
DYDan Yan
Dan Yan
WHWenjun Hou
Wenjun Hou
HJHui Jiang
Hui Jiang
MWMin Wu
Min Wu
HXHuae Xu
Huae Xu
As one of the most common cancers worldwide, non-small-cell lung cancer (NSCLC) treatment always fails owing to the tumor microenvironment and resistance. UA, a traditional Chinese medicine, was reported to have antitumor potential in tumor models in vitro and in vivo, but showed impressive results in its potential application for poor water solubility. In this study, a novel biomimetic drug-delivery system based on UA-loaded nanoparticles (UaNPs) with a red blood cell membrane (RBCM) coating was developed. The RBCM-coated UANPs (UMNPs) exhibited improved water solubility, high stability, good biosafety, and efficient tumor accumulation. Importantly, the excellent antitumor efficiency of the UMNPs was confirmed both in vitro and in vivo in cancer models. In addition, we further investigated the antitumor mechanism of UMNPs. The results of Western blotting showed that UMNPs exerted an anticancer effect by inducing the apoptosis and autophagy of NSCLC cells, which makes it superior to free UA. In addition, body weight monitoring, hematoxylin and eosin (HE) analysis, and immunohistochemical (IHC) analysis showed no significant difference between UMNPs and the control group, indicating the safety of UMNPs. Altogether, the preparation of biomimetic UMNPs provides a promising strategy to improve outcomes in NSCLC.

13 March 2025 in Oncogene
Verified
Journal Article
Closed access
PDF file
BWBangting Wang
Bangting Wang
SZShijie Zhang
Shijie Zhang
YGYumeng Guo
Yumeng Guo
WGWenqing Gao
Wenqing Gao
HWHao Wu
Hao Wu
LLLi Liu
Li Liu

21 January 2026 in Oncogene
Verified
Journal Article
Open access
PDF file
BWBangting Wang
Bangting Wang
SZShijie Zhang
Shijie Zhang
YGYumeng Guo
Yumeng Guo
WGWenqing Gao
Wenqing Gao
HWHao Wu
Hao Wu
LLLi Liu
Li Liu
In the original version of Fig. 2F, the "OE-control group" data for the HT29 cell line were inadvertently used. This panel has been replaced with the correct data in the amended figure as shown below. The authors confirm that this correction does not alter the reported results or conclusions of the manuscript. The authors agree to the modification and sincerely apologize for any inconvenience caused.